



02 March 2017

Hoffmann-La Roche Ltd
Representation in Armenia
35/11 Tumanyan St.
0002 Yerevan, Armenia
Tel +374 10 50 11 19
Fax +374 10 50 11 18

02 March 2017

HERCEPTIN (Trastuzumab): Reminder of importance of cardiac monitoring guidance during trastuzumab therapy to reduce the frequency and severity of left ventricular dysfunction and congestive heart failure (CHF).

Dear Doctor,

F. Hoffmann-La Roche in agreement with the European Medicines Agency and the Drug Safety Monitoring Department of SCIENTIFIC CENTRE OF DRUG AND MEDICAL TECHNOLOGY EXPERTISE AFTER ACADEMICIAN E. GABRIELYAN» CJSC would like to highlight the importance of the information available in the Herceptin (trastuzumab) EU SmPC with respect to cardiac monitoring.

Summary:

The objective of this DHPC is to highlight the importance of the trastuzumab cardiac monitoring information & treatment algorithm as stated in the Herceptin (trastuzumab) EU SmPC, in order to ensure appropriate management of left ventricular dysfunction and congestive heart failure (CHF).

F. Hoffmann-La Roche Ltd.
Representation in Armenia

Contact: Tel +374 10 50 11 19 (18)
Telephone: 35/11 Tumanyan St.
0002 Yerevan, Armenia

reply to: Gayane Ghazaryan
contact: email:
gayaneh.ghazaryan@roche.com
tel.: + 374 501119

Key messages for prescribing oncologists and gynaeco-oncologists are highlighted below:

- Cardiac assessments, as performed at baseline, should be repeated every 3 months during trastuzumab treatment.
- Please adhere to the stopping rules as detailed in the Herceptin (trastuzumab) EU SmPC Section 4.2: Posology and method of administration, including cases when LVEF percentage drops ≥ 10 percent points from baseline AND to below 50%, trastuzumab treatment should be suspended and a repeat LVEF assessment performed within approximately 3 weeks.
- Trastuzumab and anthracyclines should not be given concurrently in combination in the metastatic breast cancer (MBC) setting and in the adjuvant breast cancer treatment setting. Refer to Herceptin EU SmPC Section 4.4: Special warnings and precautions for use.
- Continue monitoring every 6 months following discontinuation of trastuzumab treatment until 24 months from the last administration of trastuzumab. In patients who receive anthracycline-containing chemotherapy, further monitoring is recommended, and should occur yearly up to 5 years from the last administration of trastuzumab, or longer if a continuous decrease of LVEF is observed.
- If symptomatic cardiac failure develops during trastuzumab therapy, it should be treated with standard medicinal products for CHF. Most patients who developed CHF or asymptomatic cardiac dysfunction in pivotal trials improved with standard CHF treatment consisting of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) and a beta-blocker.
- LVEF measurement continues to be the required method to monitor cardiac function; biomarkers may be a supportive tool for patients specifically at risk to experience CHF but cannot replace LVEF assessment by ECHO or MUGA.
- Prescribing physicians should highlight to other physicians responsible for the follow-up of a trastuzumab treatment patient that it is important to continue regular cardiac monitoring as per the Herceptin (trastuzumab) EU SmPC.

Background for this Cardiac Monitoring Reminder

Although there are no new cardiac safety risk signals with trastuzumab therapy, results from surveys have shown that adherence to cardiac monitoring could be improved to reduce the



frequency and severity of left ventricular dysfunction and CHF in patients treated with trastuzumab therapy.

Cardiac risk of trastuzumab therapy has been shown to be reversible in some patients upon discontinuation of trastuzumab treatment, underscoring the importance of monitoring LVEF function of patients during trastuzumab treatment and after trastuzumab treatment discontinuation.

Further Information

Therapeutic Indications

As per the currently approved Herceptin (trastuzumab) EU SmPC, Herceptin should only be used in patients with metastatic or early breast cancer and metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.

Call for Reporting

According to the Article 17 of the RA Law “On Drugs” “Health care institutions, drugstores, institutions and the organizations which are consuming and using medicines, are obliged to inform the authorized governmental body about all cases of development of unknown adverse reactions immediately” to Drug Safety Monitoring Department of Address: 49/4 Komitas av., 0051 Yerevan, Armenia.

Phone: +37410231682 (ext: 123)

Hot line for ADR reporting: + 37410237265

Email: naira@pharm.am;

Company contact point

Should you have any questions regarding the use of Herceptin, please feel free to contact us at:

Hoffmann-La Roche Ltd.
Representation in Armenia 35/11
Tumanyan St., 0002 Yerevan, Armenia
Tel +374 10 50 11 19(18) inner 103

F. Hoffmann-La Roche Ltd.
Representation in Armenia

Contact: Tel +374 10 50 11 19
Fax +374 10 50 11 18(20)
Telephone: 35/11 Tumanyan St.
0002 Yerevan, Armenia

reply to: Gayane Ghazaryan
contact: email:
gayaneh.ghazaryan@roche.com
tel.: + 374 501119
+ 374 91 796688

Annexes

1. Herceptin EU SmPC

Yours sincerely,

Gayane Ghazaryan,

Medical Manager/Local Safety Responsible
Hoffmann-La Roche Ltd.

